STUELPNAGEL JOHN R
Known title: DirectorCIK: 0001189140
Associated companies
Transaction History
| TXG | ▼ Sell | Open Market | 7,012 | $425K | 9/3/2026 | View on chart |
| TXG | ▼ Sell | Open Market | 6,814 | $423K | 9/3/2026 | View on chart |
| TXG | ▼ Sell | Open Market | 6,174 | $387K | 9/3/2026 | View on chart |
| TXG | ▼ Sell | Open Market | 17,000 | $979K | 8/11/2026 | View on chart |
| TXG | ▼ Sell | Open Market | 3,000 | $176K | 8/11/2026 | View on chart |
| TXG | ▲ Buy | Grant | 8,829 | $0 | 6/4/2026 | View on chart |
| TXG | ▲ Buy | Grant | 15,357 | $0 | 6/3/2025 | View on chart |
| TXG | ▲ Buy | Grant | 8,649 | $0 | 6/11/2024 | View on chart |
| TXG | ▲ Buy | Grant | 1,865 | $0 | 6/14/2023 | View on chart |
| TXG | ▼ Sell | Open Market | 10,000 | $549K | 6/5/2023 | View on chart |
| TXG | ▲ Buy | Grant | 2,120 | $0 | 6/15/2022 | View on chart |
| TXG | ▼ Sell | Open Market | 3,218 | $485K | 12/30/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 1,782 | $270K | 12/30/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 100 | $16K | 12/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 2,000 | $301K | 12/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 1,700 | $257K | 12/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 1,100 | $167K | 12/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 100 | $15K | 12/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 1,048 | $167K | 11/16/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 100 | $16K | 11/16/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 800 | $126K | 11/16/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 3,052 | $485K | 11/16/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 100 | $16K | 11/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 100 | $16K | 11/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 100 | $16K | 11/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 1,494 | $244K | 11/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 2,906 | $476K | 11/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 300 | $49K | 11/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 4,400 | $662K | 10/18/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 300 | $46K | 10/18/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 300 | $45K | 10/18/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 5,000 | $751K | 10/7/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 700 | $108K | 9/16/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 1,500 | $234K | 9/16/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 1,631 | $256K | 9/16/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 1,169 | $184K | 9/16/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 300 | $53K | 9/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 1,000 | $176K | 9/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 2,300 | $409K | 9/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 1,104 | $197K | 9/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 296 | $53K | 9/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
10x Genomics Partners With Fred Hutchinson Cancer Center
10x Genomics announced a new collaboration with the Fred Hutchinson Cancer Center to apply single-cell and spatial technologies to solid tumors and blood cancers. This partnership aims to advance research in hematologic malignancies. Separately, Barclays raised its price target for the stock to $110, reflecting continued analyst interest in the company's growth potential.
10x Genomics Partners With Fred Hutchinson Cancer Center. 10x Genomics announced a new collaboration with the Fred Hutchinson Cancer Center to apply single-cell and spatial technologies to solid tumors and blood cancers. This partnership aims to advance research in hematologic malignancies. Separately, Barclays raised its price target for the stock to $110, reflecting continued analyst interest in the company's growth potential.